Shots:
- Rectify has entered into a strategic research & licensing agreement with BI to accelerate the development of small molecule therapies for CKD & other conditions
- Collaboration will leverage Rectify’s positive functional modulators (PFM) platform to develop oral small molecules that restore or enhance ABCC6 function, targeting pathologic calcification to slow disease progression in CKD, Pseudoxanthoma elasticum, & generalized arterial calcification of infancy
- As per the deal, Rectify will receive an upfront payment & ~$448M in preclinical, clinical, regulatory & commercial milestones, along with tiered royalties
Ref: Rectify | Image: Rectify & BI |Press Release
Related News: Boehringer Ingelheim Receives the US FDA Approval of Jascayd (Nerandomilast) for Progressive Pulmonary Fibrosis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
